MedTrace Logo

A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine

NCT00375206 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2007-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body.

Conditions

Interventions

BIOLOGICAL

Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)

Sponsors & Collaborators

  • PowderMed

    lead INDUSTRY

Principal Investigators

  • Philip Leese, MD · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375206 on ClinicalTrials.gov